Toward DNA-Based T-Cell Mediated Vaccines to Target HIV-1 and Hepatitis C Virus: Approaches to Elicit Localized Immunity for Protection

• Published in: Frontiers in cellular and infection microbiology Vol. 9; no. APR; p. 91
• Main Authors: Mekonnen, Zelalem A, Grubor-Bauk, Branka, Masavuli, Makutiro G, Shrestha, Ashish C, Ranasinghe, Charani, Bull, Rowena A, Lloyd, Andrew R, Gowans, Eric J, Wijesundara, Danushka K
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Research Foundation 03.04.2019; Frontiers Media S.A
• Subjects: 60 APPLIED LIFE SCIENCES; Cellular and Infection Microbiology; DNA vaccine; Drug Discovery - trends; HCV; hepatitis C; Hepatitis C - prevention & control; HIV Infections - prevention & control; HIV/AIDS; human immunodeficiency virus; Humans; T cell immunity; T-Lymphocytes - immunology; tissue-resident memory; Vaccines, DNA - immunology; Vaccines, DNA - isolation & purification; Vaccinology - trends; Viral Vaccines - immunology; Viral Vaccines - isolation & purification; DNA vaccine; HIV/AIDS; hepatitis C; tissue-resident memory; T cell immunity; human immunodeficiency virus; HCV
• ISSN: 2235-2988; 2235-2988
• DOI: 10.3389/fcimb.2019.00091

Human immunodeficiency virus (HIV)-1 and hepatitis C virus (HCV) are major contributors to the global disease burden with many experts recognizing the requirement of an effective vaccine to bring a durable end to these viral epidemics. The most promising vaccine candidates that have advanced into pre-clinical models and the clinic to eliminate or provide protection against these chronic viruses are viral vectors [e.g., recombinant cytomegalovirus, Adenovirus, and modified vaccinia Ankara (MVA)]. This raises the question, is there a need to develop DNA vaccines against HIV-1 and HCV? Since the initial study from Wolff and colleagues which showed that DNA represents a vector that can be used to express transgenes durably , DNA has been regularly evaluated as a vaccine vector albeit with limited success in large animal models and humans. However, several recent studies in Phase I-IIb trials showed that vaccination of patients with recombinant DNA represents a feasible therapeutic intervention to even cure cervical cancer, highlighting the potential of using DNA for human vaccinations. In this review, we will discuss the limitations and the strategies of using DNA as a vector to develop prophylactic T cell-mediated vaccines against HIV-1 and HCV. In particular, we focus on potential strategies exploiting DNA vectors to elicit protective localized CD8 T cell immunity in the liver for HCV and in the cervicovaginal mucosa for HIV-1 as localized immunity will be an important, if not critical component, of an efficacious vaccine against these viral infections.